On a path toward a broad-spectrum anti-viral: inhibition of HIV-1 and coronavirus replication by SR kinase inhibitor harmine

• Published in: Journal of virology 2023-10, Vol.97 (10), p.e0039623-e0039623
• Main Authors: Dahal, Subha, Clayton, Kiera, Cabral, Tyler, Cheng, Ran, Jahanshahi, Shahrzad, Ahmed, Choudhary, Koirala, Amrit, Villasmil Ocando, Alonso, Malty, Ramy, Been, Terek, Hernandez, Javier, Mangos, Maria, Shen, David, Babu, Mohan, Calarco, John, Chabot, Benoit, Attisano, Liliana, Houry, Walid A, Cochrane, Alan
• Format: Article
• Language: English
• Subjects: Vaccines and Antiviral Agents
• ISSN: 0022-538X; 1098-5514
• DOI: 10.1128/jvi.00396-23

This study highlights the crucial role RNA processing plays in regulating viral gene expression and replication. By targeting SR kinases, we identified harmine as a potent inhibitor of HIV-1 as well as coronavirus (HCoV-229E and multiple SARS-CoV-2 variants) replication. Harmine inhibits HIV-1 protein expression and reduces accumulation of HIV-1 RNAs in both cell lines and primary CD4 T cells. Harmine also suppresses coronavirus replication post-viral entry by preferentially reducing coronavirus sub-genomic RNA accumulation. By focusing on host factors rather than viral targets, our study offers a novel approach to combating viral infections that is effective against a range of unrelated viruses. Moreover, at doses required to inhibit virus replication, harmine had limited toxicity and minimal effect on the host transcriptome. These findings support the viability of targeting host cellular processes as a means of developing broad-spectrum anti-virals.